POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF SUNITINIB (SU) IN GASTROINTESTINAL STROMAL TUMOR (GIST) AND RENAL CELL CARCINOMA (RCC) PATIENTS

Khosravan R.; Mugundu G. M.; Casali P. G.; Rini B. I.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF SUNITINIB (SU) IN GASTROINTESTINAL STROMAL TUMOR (GIST) AND RENAL CELL CARCINOMA (RCC) PATIENTS

【24h】

POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF SUNITINIB (SU) IN GASTROINTESTINAL STROMAL TUMOR (GIST) AND RENAL CELL CARCINOMA (RCC) PATIENTS

机译：SUNITINIB（SU）在胃肠道间质瘤（GIST）和肾细胞癌（RCC）患者中的种群药动学和药代动力学模型

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2014年第1期|共2页
作者
Khosravan R.; Mugundu G. M.; Casali P. G.; Rini B. I.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF SUNITINIB (SU) IN GASTROINTESTINAL STROMAL TUMOR (GIST) AND RENAL CELL CARCINOMA (RCC) PATIENTS [J] . Khosravan R., Mugundu G. M., Casali P. G., Clinical Pharmacology and Therapeutics . 2014,第Suppla1期

机译：SUNITINIB（SU）在胃肠道间质瘤（GIST）和肾细胞癌（RCC）患者中的种群药动学和药代动力学模型
2. 4526 POSTER Safety profile of single-agent sunitinib malate from the French Temporary Authorization for Use program (Cohort ATU) in metastatic renal cell carcinoma (MRCC) after failure of treatment with cytokines and gastrointestinal stromal tumor (GIST) patients after failure of imatinib mesylate treatment [J] . S.Oudard, S.Negrier, J.M.Ferrero, European Journal of Cancer Supplements . 2007,第4期

机译：4526 POSTER法国细胞因子和胃肠道间质瘤（GIST）治疗失败后，法国临时使用许可程序（Cohort ATU）单剂苹果酸舒尼替尼在转移性肾细胞癌（MRCC）中的安全性
3. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor [J] . Khosravan Reza, Motzer Robert J., Fumagalli Elena, Clinical pharmacokinetics . 2016,第10期

机译：晚期肾细胞癌或胃肠道间质瘤患者的给药方案对舒尼替尼的群体药代动力学/药效学建模
4. New DCE-MRI parameters to quantify the vascular changes induced by sunitinib treatment in renal carcinoma tumors [C] . Al-Bashir Areen K., Hillman Gilda G., Li Meng, Middle East Conference on Biomedical Engineering . 2014

机译：新的DCE-MRI参数可量化舒尼替尼治疗在肾癌肿瘤中诱导的血管变化
5. Phosphatidylinositol Remodeling Through Membrane Bound O-Acyl Transferase Domain-7 (MBOAT7) Promotes the Progression of Clear Cell Renal Cell Carcinoma (ccRCC) [D] . Neumann, Chase K. A. 2020

机译：通过膜结合的磷脂酰肌醇通过膜结合O-酰基转移酶结构域-7（MBOAT7）促进透明细胞肾细胞癌的进展（CCRCC）
6. PopulationPharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patientswith Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor [O] . Reza Khosravan, Robert J. Motzer, Elena Fumagalli, -1

机译：人口舒尼替尼在患者中的给药方案的药代动力学/药效学模型晚期肾细胞癌或胃肠道间质瘤
7. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor [O] . Reza Khosravan, Robert J. Motzer, Elena Fumagalli, 2016

机译：晚期肾细胞癌或胃肠道间质瘤患者的给药方案对舒尼替尼的群体药代动力学/药效学建模

POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF SUNITINIB (SU) IN GASTROINTESTINAL STROMAL TUMOR (GIST) AND RENAL CELL CARCINOMA (RCC) PATIENTS

著录项

相似文献

相关主题

期刊订阅